Business Wire

Q4 Inc. to Report Third Quarter 2021 Results on November 10th

Share

Q4 Inc. (TSX: QFOR), a leading capital markets communications platform, intends to release its third quarter 2021 results before the market opens on Wednesday, November 10, 2021. In conjunction with this release, the company will hold a live video webcast on the new Q4 Virtual Events Platform at 8:30 a.m. EST on November 10, 2021. The event will be hosted by Darrell Heaps, Chief Executive Officer, and Ryan Levenberg, Chief Financial Officer.

Participants can register in advance or access the webcast live at https://events.q4inc.com/attendee/490811698. Supplemental materials will be available at least fifteen minutes prior to the start of the event. A replay of the webcast will be available at investors.q4inc.com shortly after the event concludes.

Audience questions will be taken real-time via the Q4 Platform. Investors can also submit their questions in advance to ir@q4inc.com or via our IR website. We will do our best to respond to your questions either on the webcast, if time permits or shortly thereafter. We appreciate your interest.

About Q4 Inc.

Q4 Inc. (Q4) is a leading capital markets communications platform that is transforming the way publicly traded companies, investors and investment banks make decisions to efficiently discover, communicate and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets CRM, shareholder and market analytics tools. The firm is a trusted partner to more than 2,500 public companies globally including 50% of the S&P 500. Q4 is based in Toronto, with offices in New York and London. Learn more at q4inc.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations Contact:
Matt Tractenberg, ir@q4inc.com

Media Inquiries:
Karen Greene, media@q4inc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients29.11.2021 17:00:00 EET | Press release

Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases, has selected AWS as its preferred cloud provider. Innovating on AWS and with the help of AWS experts and partners in healthcare and life sciences, Gilead provides its data scientists with the latest advances in machine learning and analytics. These capabilities fuel data-driven decision making across the organization—from biomarker discovery through manufacturing and clinical trial recruitment—and deliver insights that can help Gilead refine its drug pipeline. The company also relies on AWS to host all workloads for its enterprise resource planning (ERP) transformation project to implement SAP S/4HANA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005047/en/ “With AWS as our pre

Celltrion accelerates development of nebulised cocktail therapy (CT-P63 in combination with CT-P59) using its antibody platform to tackle new COVID-19 variants29.11.2021 16:08:00 EET | Press release

Celltrion Group announced today that the company has accelerated development of a nebulised formulation of its neutralising antibody cocktail treatment, to respond to emerging mutants from SARS-CoV-2. Targeting newly emerging mutations of SARS-CoV-2 and using its already constructed antibody platform, Celltrion has developed a neutralising antibody cocktail consisting of CT-P63 together with its monoclonal antibody treatment Regkirona (regdanvimab, CT-P59), which was recently approved by the European Commission (EC) for the treatment of COVID-19. Celltrion enrolled 24 healthy volunteers in its global phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics of CT-P63 and the company anticipates results by the end of the year. CT-P63 is a monoclonal antibody targeting SARS-CoV-2 spike receptor binding domain (RBD) as a treatment for COVID-19 infection. Celltrion plans to evaluate neutralisation of new emerging variants tailored to specific regions and assess poten

FourKites Appoints Industry Veteran to Accelerate Supply Chain Visibility Among European Carriers and Logistics Providers29.11.2021 13:12:00 EET | Press release

Oleksii Kosenko joins FourKites®, the world’s leading real-time supply chain visibility platform, as Director Carrier Network Operations, EMEA, to accelerate the company’s rapidly growing carrier base in Europe. Prior to joining FourKites, Kosenko led the carrier sales teams at Uber Freight and sennder Technologies GmbH, and held a senior sales role at C.H. Robinson. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005303/en/ Oleksii Kosenko joins FourKites as Director Carrier Network Operations, EMEA (Photo: Business Wire) "As today’s supply chain challenges put increasing pressure on carriers across the world, my priority is to ensure that European carriers of all sizes can leverage FourKites to offer better customer service, improve cash flow and cut costs," says Kosenko. "Being able to provide a secure platform for sharing data is what will propel the entire supply chain visibility market into the future, and carrier

Galderma to Acquire Award-winning ALASTIN Skincare® Enhancing Its Integrated Dermatology Platform to Continue Delivering the Best Experience to Patients29.11.2021 13:00:00 EET | Press release

Galderma, the world’s largest independent dermatology company, announced that it has signed a definitive agreement to acquire ALASTIN Skincare®, Inc. (“ALASTIN”), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. The acquisition is subject to customary closing conditions and necessary regulatory approvals. Financial terms of the transaction have not been disclosed. ALASTIN’s premium skincare portfolio is fully incremental to and synergistic with Galderma’s integrated dermatology platform. Founded in 2015, ALASTIN provides a comprehensive collection of cutting-edge, scientifically-proven products for daily skincare regimens and peri-procedural use. ALASTIN’s product offerings are backed by its patented TriHex Technology®, a proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin. Since inception, ALASTIN has delivered rapid and consistent sales growth, achieving a CAGR

Celonis Accelerates its Process Mining and Execution Management Leadership in India29.11.2021 11:53:00 EET | Press release

Celonis, the global leader in execution management, today announced that it will expand its process mining and execution management operations into India. Celonis believes the opportunity for customers, global system integrators (GSIs), business process outsourcing (BPO) providers, consultants, and academics is as big as the shift from on-prem to cloud. As part of its execution management initiative in India, Celonis has committed to investing over $100 million dollars into the Indian process industry and expects to create more than 1,000 jobs. The expansion into India enables the world’s leading business process professionals and experts to unlock billions in new process and execution value for both their customers and within their own companies. The Celonis execution management initiative was launched at a multi-day press conference and partner ecosystem event in Bangalore, India. The opportunity for process mining and execution management in India is immense. To provide context, Eve

REPLY: “Cloud in Financial Services” Report Shows Cloud Services Transforming How Value Is Created in the Financial Services Sector29.11.2021 11:30:00 EET | Press release

“Cloud in Financial Services”, a joint report by Reply and Imperial College Business School, provides a one of a kind, in-depth look at how the cloud is set to transform financial services. “Cloud services are here to stay within financial services and the pandemic has only accelerated the move” – commented Nelson Phillips, Professor of Technology Management at the University of California (formerly Professor of Innovation and Strategy and Associate Dean of External Relations at Imperial College Business School) – “But financial institutions need to be strategic in the adoption and there are important questions that need to be addressed as firms progressively move more activity to the cloud. There are significant strategic and organisational challenges that need to be dealt with to ensure cloud adoption is successful and that firms derive maximum value from the move.” Naturally, “Cloud in Financial Services” takes these strategic and organizational challenges head on, addressing the ma

Masimo Rad-G® Helps Clinicians Identify Pediatric Pneumonia in Large Field Trial in India29.11.2021 10:00:00 EET | Press release

Masimo (NASDAQ: MASI) today announced the findings of a study published in Clinical Medicine Insights: Pediatrics in which Dr. Harish Kumar and colleagues at IPE Global in New Delhi, India reported on their experience using the Masimo Rad-G® Pulse Oximeter to aid health providers in pneumonia case detection and management in more than 4,500 children under five years who presented with symptoms of acute respiratory infection (ARI). Rad-G is a rugged, portable, handheld Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximeter and noninvasive respiration rate monitor from the pleth (RRp®). The researchers found that Rad-G was “highly acceptable among health workers” and aided the “timely classification and treatment” of pneumonia—helping them achieve correct case management in more than 91% of cases of ARI and reduce the unnecessary use of antibiotics.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211128005235/en/

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom